Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial

• Autores principales: Mojgan Karimi-Zarchi (Autor), Leila Allahqoli (Autor), Ameneh Nehmati (Autor), Abolfazl Mehdizadeh Kashi (Autor), Shokouh Taghipour-Zahir (Autor), Ibrahim Alkatout (Autor)
• Formato: Libro
• Publicado: BMC, 2020-02-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Background Human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. The HPV vaccine has a very significant impact on the incidence of cervical cancer. The present study aimed to investigate the impact of prophylactic quadrivalent HPV vaccine in the treatme...